Low-molecular-weight heparin in patients with advanced cirrhosis.


BACKGROUND & AIMS The use of low-molecular-weight heparins (LMWH) in patients with advanced liver diseases is frequently avoided because of the enhanced risk of bleeding complications. However, many patients with impaired liver function are at a high risk of thrombosis or have an indication for therapeutic anticoagulation. Therefore, the aim of this study… (More)
DOI: 10.1111/j.1478-3231.2010.02358.x

4 Figures and Tables


  • Presentations referencing similar topics